Incidence of autoimmunity in a phase 3 trial: Comparison of alemtuzumab and Rebif® in multiple sclerosis I (CARE-MS I)

Authors
Category Primary study
JournalNeurology
Year 2012
This article has no abstract
Epistemonikos ID: a05a2b834f020d3b67488648a447b2b617402c44
First added on: Nov 18, 2025